Targeting METTL3 as a checkpoint to enhance T cells for tumour immunotherapy
Clinical and Translational Medicine · 2024-11 · 14 (11)
DOI: 10.1002/ctm2.70089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 20.11.2024. Verfasst von Kaixin Wu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cell Lineage and Atlas, Bioland Laboratory, Guangzhou Regenerative Medicine and Health GuangDong Laboratory, Guangzhou, China. Hauptthemen laut MEDLINE: Methyltransferases, Immunotherapy, Tumor Microenvironment. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Science and Technology Projects in Guangzhou.
Abstract (Originalsprache)
Background
Immunotherapy has emerged as a crucial treatment modality for solid tumours, yet tumours often evade immune surveillance. There is an imperative to uncover novel immune regulators that can boost tumour immunogenicity and increase the efficacy of immune checkpoint blockade (ICB) therapy. Epigenetic regulators play critical roles in tumour microenvironment remodelling, and N6‐methyladenosine (m 6 A) is known to be involved in tumourigenesis. However, the role of m 6 A in regulating T‐cell function and enhancing anti‐tumour immunity remains unexplored.
Methods
Several cancer cell lines were treated with STM2457, an enzymatic inhibitor of RNA m 6 A methyltransferase METTL3, and explored the transcriptome changes with RNA sequencing (RNA‐seq). We then utilised mouse melanoma (B16) and mouse colorectal adenocarcinoma (MC38) models to investigate the effects of METTL3 inhibition on immunotherapy, and analysed the dynamics of the tumour microenvironment via single‐cell RNA‐seq (scRNA‐seq). Furthermore, in vitro and in vivo T‐cell cytotoxicity killing assay and CRISPR Cas9‐mediated m 6 A reader YTHDF1‐3 knockout in B16 were performed to assess the role and the molecular mechanism of RNA m 6 A in tumour killing. Finally, the efficacy of METTL3 inhibition was also tested on human melanoma model (A375) and human T cells.
Results
We demonstrate that inhibiting METTL3 augments tumour immunogenicity and sustains T‐cell function, thereby enhancing responsiveness to ICB therapy. Mechanistically, METTL3 inhibition triggers an interferon response within tumour cells, amplifying the anti‐tumour immune response, along with deletion of the m 6 A reader protein YTHDF2 in tumours inhibiting major histocompatibility complex (MHC)‐I degradation. Remarkably, these anti‐tumour effects are reliant on the immune system. Specifically, METTL3 inhibition enhances interferon‐gamma (IFNγ) and granzyme B (GzmB) expression, thereby strengthening T‐cell killing ability, and concurrently dampening the expression of exhaustion‐related genes.
Conclusion
Targeting METTL3 enhances anti‐tumour immunity by boosting T‐cell cytotoxicity and reversing T‐cell exhaustion. Our study positions METTL3 as an epigenetic checkpoint, highlighting the potential of targeting METTL3 to invigorate intrinsic anti‐tumour defenses and overcome immune resistance. Key points Targeting METTL3 augments tumour cell immunogenicity and sustains T‐cell function. T cell with METTL3 inhibition can reverse T‐cell exhaustion, and promote expression of IFNγ and GzmB, thereby enhancing cytotoxicity in anti‐PD‐1 therapy. YTHDF2 deletion in tumours prolong the lifespan of MHC‐I mRNAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cell Lineage and Atlas, Bioland Laboratory, Guangzhou Regenerative Medicine and Health GuangDong Laboratory, Guangzhou, China.
- The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
- Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou Medical University, Guangzhou, China.
- Center for Cell Lineage and Development, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
- University of Chinese Academy of Sciences, Beijing, China.
- Guangzhou National Laboratory, Guangzhou, China.
ORCID-Profile: Kaixin Wu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Science and Technology Projects in Guangzhou
- Guangdong Basic and Applied Basic Research Foundation
- Guangdong Natural Science Funds for Distinguished Young Scholar
- Basic Research Project of Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
- Science and Technology Planning Project of Guangdong Province, China
- Innovation Technology Commission of the Hong Kong SAR, China
Zitieren
APA
Wu, K., Li, S., Hong, G., Dong, H., Tang, T., Liu, H., Jin, L., Lin, S., Ji, J., Hu, M., Chen, S., Wu, H., Luo, G., Wu, H., Kong, X., Chen, J., He, J., & Wu, H. (2024). Targeting METTL3 as a checkpoint to enhance T cells for tumour immunotherapy. Clinical and Translational Medicine, 14(11). https://doi.org/10.1002/ctm2.70089
Vancouver
Wu K, Li S, Hong G, Dong H, Tang T, Liu H, et al. Targeting METTL3 as a checkpoint to enhance T cells for tumour immunotherapy. Clinical and Translational Medicine. 2024;14(11). doi:10.1002/ctm2.70089
BibTeX
@article{Wu2024,
author = {Wu, Kaixin and Li, Sa and Hong, Guangliang and Dong, Hongzhi and Tang, Tongke and Liu, He and Jin, Lingmei and Lin, Siyuan and Ji, Jingyun and Hu, Mingli and Chen, Shuntian and Wu, Haoyuan and Luo, Guanzheng and Wu, Haoyuan and Kong, Xiangqian and Chen, Jiekai and He, Jiangping and Wu, Hongling},
title = {Targeting METTL3 as a checkpoint to enhance T cells for tumour immunotherapy},
journal = {Clinical and Translational Medicine},
year = {2024},
volume = {14},
number = {11},
doi = {10.1002/ctm2.70089}
}
EUVIMED